Trial Profile

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GEN 1044 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Uterine cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Genmab

Most Recent Events

10 Dec 2021 Status changed from active, no longer recruiting to discontinued.
25 Oct 2021 This trial has been suspended in Spain according to European Clinical Trials Database record.
20 Oct 2021 Planned End Date changed from 1 Jun 2024 to 15 Jan 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com